SNGX (Soligenix) Moat Score: 3/10 (As of Jul. 09, 2026)


SNGX Soligenix Inc SNGX
23 GF Score
Price $0.37
! 1 Warning Sign
View Full Analysis

What is Soligenix Moat Score?

Soligenix SNGX -1.25% 23 Moat Score is 3 as of Jul. 09, 2026. GuruFocus rates SNGX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, Soligenix ranks better than 75.54% on this metric.

Soligenix has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Soligenix has No Moat: Soligenix operates in the biotech sector with some intellectual property, but lacks market leadership and strong brand strength. The company faces high competition and regulatory challenges, with limited pricing power and customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Soligenix might have No Moat - Very weak/transient advantages.

Soligenix  (NAS:SNGX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Soligenix Moat Score Related Terms

SNGX vs BCAB, APM, LABT: Moat Score Comparison

For the Biotechnology subindustry, Soligenix's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Moat Score distribution charts can be found below:

* The bar in red indicates where Soligenix's Moat Score falls into.


SNGX
23GF Score
Soligenix Inc SNGX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Soligenix (SNGX) has a Moat Score of 3 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Soligenix ranks #341 out of 1394 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Soligenix's Moat Score too high?
Soligenix's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Soligenix's value of 3 is 50% above this industry median. Based on the distribution chart, Soligenix ranks #341 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soligenix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Soligenix's Moat Score compare to BCAB and APM?
According to the Biotechnology industry distribution chart, Soligenix ranks #341 out of 1394 companies for Moat Score. This places Soligenix in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Soligenix's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Soligenix's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Soligenix's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soligenix stock overvalued right now?
Soligenix (SNGX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Soligenix's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Soligenix (SNGX), the current Moat Score is 3 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Soligenix Business Description

Other Exchanges 0A6I:UK
Address 29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
23GF Score

Get the complete analysis for SNGX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price